Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (type 5) by sildenafil and related compounds

Molecular Pharmacology

Volumn 56, Issue 1, 1999, Pages 124-130

  Turko, Illarion V ^a   Ballard, Stephen A ^b   Francis, Sharron H ^a   Corbin, Jackie D ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC ACID; CYCLIC GMP; CYCLIC GMP PHOSPHODIESTERASE; HISTAMINE; PHOSPHODIESTERASE INHIBITOR; SILDENAFIL; TYROSINE; ZAPRINAST;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CORPUS CAVERNOSUM; DRUG INHIBITION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME ACTIVE SITE; ENZYME ACTIVITY; MUTAGENESIS; NONHUMAN; PENIS ERECTION; PRIORITY JOURNAL;

EID: 0032993016     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.56.1.124     Document Type: Article

References (35)

1. Andrews P (1986) Functional groups, drug-receptor interactions and drug design. Trends Pharmacol 7:148-151.
2. Ballard SA, Gingell CJ, Tang K, Turner LA, Price ME and Naylor AM (1998) Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J Urol 159:2164-2171.
3. Beltman J, Becker DE, Butt E, Jensen GS, Rybalkin SD, Jastorff B and Beavo J (1995) Characterization of cyclic nucleotide phosphodiesterases with cyclic GMP analogs: Topology of the catalytic domains. Mol Pharmacol 47:330-339.
4. Boolell M, Gepi-Attee S, Gingell JC and Allen MJ (1996) Sildenafil, a novel effective oral therapy for male erectile dysfunction. Sr J Urol 78:257-261.
5. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
6. Braner DA, Fineman JR, Chang R and Soifer SJ (1993) M&B 22948, a cGMP phosphodiesterase inhibitor, is a pulmonary vasodilator in lambs. Am J Physiol 264:H252-H258.
7. Chuang AT, Strauss JD, Murphy RA and Steers WD (1998) Sildenafil, a type-5 cGMP phosphodiesterase inhibitor, specifically amplifies endogenous cGMP-dependent relaxation in rabbit corpus cavernosum smooth muscle in vitro. J Urol 160:257-261.
8. Clarke WR, Uezono S, Chambers A and Doepfner P (1994) The type-III phosphodiesterase inhibitor milrinone and type-V PDE inhibitor dipyridamole individually and synergistically reduce elevated pulmonary vascular resistance. Pulm Pharmacol 7:81-89.
9. Czarniecki M, Sybertz EJ and Ahn HS (1996) Inhibitors of type I and V phosphodiesterase: Elevation of cGMP as a therapeutic strategy. Annu Rep Med Chem 31:61-70.
10. Fersht AR, Shi JP, Knill-Jones J, Lowe DM, Wilkinson AJ, Blow DM, Brick P, Carter P, Waye MMY and Winter G (1985) Hydrogen bonding and biological specificity analysed by protein engineering. Nature (Land) 314:235-238.
11. Francis SH, Lincoln TM and Corbin JD (1980) Characterization of a novel cGMP binding protein from rat lung. J Biol Chem 255:620-626.
12. Francis SH, Noblett BD, Todd BW, Wells JN and Corbin JD (1988) Relaxation of vascular and tracheal smooth muscle by cyclic nucleotide analogs that preferentially activate cGMP-dependent protein kinase. Mol Pharmacol 34:506-517.
13. Furchgott RF (1984) The role of endothelium in the responses of vascular smooth muscle to drugs. Annu Rev Pharmacol Toxicol 24:175-197.
14. Jeremy JY, Ballard SA, Naylor AM, Miller MAW and Angelini GD (1997) Effects of sildenafil, a type-5 cGMP phosphodiesterase inhibitor, and papaverine on cyclic GMP and cyclic AMP levels in the rabbit corpus cavernosum in vitro. Br J Urol 79:958-963.
15. Hamet P and Coquil JF (1978) Cyclic GMP binding and cyclic GMP phosphodiesterase in rat platelets. J Cyclic Nucleotide Res 4:281-290.
16. Harris AL, Lemp BM, Bentley RG, Perrone MH, Hamel LT and Silver PJ (1989) Phosphodiesterase isozyme inhibition and the potentiation by zaprinast of endothelium-derived relaxing factor and guanylate cyclase stimulating agents in vascular smooth muscle. J Pharmacol Exp Ther 249:394-400.
17. Ichinose F, Adrie C, Hurford WE and Zapol WM (1995) Prolonged pulmonary vasodilator action of inhaled nitric oxide by zaprinast in awake lambs. J Appl Physiol 78:1288-1295.
18. Ignarro LJ, Byrns RE, Buga GM and Wood KS (1987) Endothelium-derived relaxing factor from pulmonary artery and vein possesses pharmacologic and chemical properties identical to those of nitric oxide radical. Circ Res 61:866-879.
19. Kotera J, Yanaka N, Fujishige K, Imai Y, Akatsuka H, Ishizuka T, Kawashima K and Omori K (1997) Expression of rat cGMP-binding cGMP-specific phosphodiesterase mRNA in Purkinje cell layers during postnatal neuronal development. Eur J Biochem 249:434-442.
20. Lincoln TM, Kornalavilas P and Cornwell TL (1994) Pleoitropic regulation of vascular smooth muscle tone by cyclic GMP-dependent protein kinase. Hypertension 23:1141-1147.
21. Loughney K, Hill TR, Florio VA, Uher L, Rosman GJ, Wolda SL, Jones BA, Howard ML, McAllister-Lucas LM, Sonnenburg WK, Francis SH, Corbin JD, Beavo JA and Ferguson K (1998) Isolation and characterization of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3′,5′-cyclic nucleotide phosphodiesterase. Gene 216:139-147
22. McAllister-Lucas LM, Haik TL, Colbran JL, Sonnenburg WK, Seger D, Turko IV, Beavo JA, Francis SH and Corbin JD (1995) An essential aspartic acid at each of two allosteric cGMP-binding sites of a cGMP-specific phosphodiesterase. J Biol Chem 270:30671-30679.
23. McAllister-Lucas LM, Sonnenburg WK, Kadlecek A, Seger D, Le Trong H, Colbran JL, Thomas MK, Walsh KA, Francis SH, Corbin JD and Beavo JA (1993) The structure of a bovine lung cGMP-binding, cGMP-specific phosphodiesterase deduced from a cDNA clone. J Biol Chem 268:22863-22873.
24. McMahon TJ, Ignarro LJ and Kadowitz PJ (1993) Influence of zaprinast on vascular tone and vasodilator responses in the cat pulmonary vascular bed. J Appl Physiol 74:1704-1711.
25. Moreland RB, Goldstein I and Traish A (1998) Sildenafil, a novel inhibitor of phosphodiesterase type 5 in human corpus cavernosum smooth muscle cells. Life Sci 62:309-318.
26. Palmer RMJ, Ferrige AG and Moncada S (1987) Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature (Lond) 327:524-526.
27. Sekhar KR, Grondin P, Francis SH and Corbin JD (1996) Design and Synthesis of xanthines and cyclic GMP analogues as potent inhibitors of PDE5, in Handbook of Immunopharmacology (Schudt C ed) pp 135-146, Academic Press, New York.
28. Silver PJ (1996) Inhibition of phosphodiesterase isoenzymes and cell function by selective PDE5 inhibitors, in Handbook of Immunopharmacology (Schudt C ed) pp 127-134, Academic Press, New York.
29. Somlyo AP and Somlyo AV (1994) Signal transduction and regulation in smooth muscle. Nature (Lond) 372:231-236.
30. Stacey P, Rulten S, Dapling A and Phillips C (1998) Molecular cloning and expression of human cGMP-binding cGMP-specific phosphodiesterase (PDE5). Biochem Biophys Res Commun 247:249-254.
31. Sybertz EJ, Czarniecki M and Ahn HS (1995) cGMP phosphodiesterase inhibition: A new mechanism for the discovery of therapeutic agents. Curr Pharm Des 1:373-390.
32. Thomas MK, Francis SH and Corbin JD (1990) Characterization of a bovine lung cGMP binding phosphodiesterase. J Biol Chem 265:14964-14970.
33. Turko IV, Francis SH and Corbin JD (1998a) Potential roles of conserved amino acids in the catalytic domain of the cGMP-binding cGMP-specific phosphodiesterase (PDE5). J Biol Chem 273:6460-6466.
34. Turko IV, Francis SH and Corbin JD (1998b) Hydropathic analysis and mutagenesis of the catalytic domain of the cGMP-binding cGMP-specific phosphodiesterase (PDE5). CGMP versus cAMP substrate selectivity. Biochemistry 37:4200-4205.
35. nD motif for cGMP binding. J Biol Chem 271:22240-22244.